Bladder cancer treatment co Vessi Medical raises $16.5m

Vincent Tchenguiz Photo: Christopher Ratcliffe
Vincent Tchenguiz Photo: Christopher Ratcliffe

Vessi's minimally invasive solution for NMIBC provides a new therapeutic alternative to transurethral resection of bladder tumor.

Israeli urology medical device company Vessi Medical today announced the completion of a $16.5 million Series A financing round for its cryotherapy technology to treat non muscle invasive bladder cancer (NMIBC). The leading investors in the round are an undisclosed global strategic investor, ALIVE- Israel HealthTech Fund, Agriline, a trust of which UK investor Vincent Tchenguiz is a discretionary beneficiary, have joined founding investor The Trendlines Group.

Vessi's minimally invasive solution for NMIBC provides a new therapeutic alternative to transurethral resection of bladder tumor (TURBT), the costly leading invasive surgical first-line therapy. NMIBC is defined as a cancer on the surface of the inner lining of the bladder. The company's bladder-specific proprietary cryotherapy has the potential for significantly improving quality of life and the technology has been successfully used in a first in human study.

Vessi Medical founder & CEO Eyal Kochavi said,, "The participation of a global strategic investor in this round is a huge show of confidence in Vessi’s achievements and potential. The financing led by ALIVE will support expanding Vessi’s R&D capabilities, clinical studies in Israel and the US, and regulatory clearance, enabling us to achieve our goal of bringing Vessi’s treatment for NMIBC to patients and physicians to reduce side effects, improve patient outcomes, and lower health care costs."

Vincent Tchenguiz, owner of Consensus Business Group and Agriline discretionary beneficiary said, "Positioned at the vanguard of technological advancement, Vessi Medical's cutting-edge cryotherapy for NMIBC heralds a transformative shift in both cancer care and health economics. Our investment is a testament to our confidence in Vessi's revolutionary potential to not only enhance patient outcomes but also to redefine care standards, alleviate suffering, and spearhead the development of more compassionate and efficacious treatment modalities."

Published by Globes, Israel business news - en.globes.co.il - on February 14, 2024.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.

Vincent Tchenguiz Photo: Christopher Ratcliffe
Vincent Tchenguiz Photo: Christopher Ratcliffe
Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Isracard shareholders approve acquisition by Delek

For the deal to go through, approval is now needed from the Supervisor of Banks and the Israel Competition Authority.

Air Canada Photo: Shutterstock Air Canada to resume Israel flights in June

The Canadian airline will resume Toronto-Tel Aviv flights on June 8 and Montreal-Tel Aviv flights in August.

NICE CEO Scott Russell credit: SAP NICE Systems falls sharply on disappointing 2025 guidance

NICE sees $693-703 million revenue in the first quarter of 2025, up 6% from the corresponding quarter of 2024, with non-GAAP earnings per share of $2.78-2.88 - 3.8% below the analysts' consensus for revenue and 2.4% below for profit.

Tel Aviv credit: Shutterstock Urban renewal plan approved in heart of Tel Aviv

The plan for the Hahashmal neighborhood opposite the Old Central Bus Station includes a 30-floor tower.

Smartshooter credit: Smartshooter Germany buys Kibbutz Yagur's Smartshooter AI sights

The product family includes systems mounted on personal rifles, remotely controlled systems, and systems carried by vehicles, robots, and even drones.

Chinese ship in Suez Canal credit: Suez Canal Authority Direct shipping to Israel could resume soon

The first shipments of vehicles are likely to reach Israel via the Suez Canal in the coming months.

Sde Dov credit: Guy Yehieli Sde Dov land prices down over 40%

Four huge tenders for almost 4,000 homes, which have been successfully marketed in the north Tel Aviv district, reflect prices over 40% lower than in 2022.

Wix president Nir Zohar credit: Alan Tzatzkin Wix provides cautious 2025 guidance after strong 2024

The Israeli website building platform company reported its first-ever GAAP operating profit in 2024.

Saar Yoskovitz and Gal Shaul  / Photo: Augury Israeli industrial AI co Augury raises $75m

The new round represents an increase in valuation for Augury, which maintains its position as a ‘unicorn’ startup.

Eitan Yochananof and Eyal Ravid credit: Eyal Izhar and Tali Bogdanovsky Regulator indicts Victory, Yochananof CEOs over price fixing

The Israel Competition Authority today issued first indictments, following the food price fixing investigation.

Shekel credit: Shutterstock Vladirina 32 Shekel gains continue as Gaza talks progress

The shekel continues to trade at its strongest levels against the dollar since early 2023.

New York credit: Shutterstock Tel Aviv - New York fares stay high despite US airlines return

Ticket prices to the US will continue to cost at least $1,200 return, according to Ophir Tours, with most fares ranging between $1,500 and $2,000, or even more.

Greenfield Partners team credit: Eyal Toueg Greenfield Partners closes $400m third fund

The funds were raised from institutional investors in Israel, the US, Europe and Asia and brings the total funds under management to more than $1 billion.

Blockaid founders Ido Ben-Natan and Raz Niv credit: Liron Weissman Israeli onchain security co Blockaid raises $50m

Blockaid protects the largest companies building onchain, including Coinbase, Metamask, Stellar, Uniswap, and World App.

Air Haifa  credit: ATR Air Haifa to launch Paphos flights

New Israeli airline Air Haifa will launch a new route between Haifa and Paphos in Cyprus on April 3, 2025 with six weekly flights.

Bladeranger Deepsolar credit: PR Bladeranger divests Deepsolar to Painreform in strategic move

Deepsolar, acquired by Bladeranger in early 2023, is a sophisticated software solution designed to optimize the management of photovoltaic solar energy fields.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018